Background: Bacterial infection in patients with liver failure can lead to a dramatic clinical deterioration. The indications for liver transplantation and outcome in these patients is still controversial.
Introduction
Patients with liver cirrhosis have a high susceptibility to infection owing to alterations in the gut microbiota, intestinal barrier dysfunction, genetic predisposition and immune dysfunction 1 . Within this context, acute-on-chronic liver failure can develop as a result of a superimposed infection 2 . According to guidelines for the evaluation of candidates for liver transplantation, patients with active infection should be treated before listing, and those who develop infection while on the waiting list should be removed until the infection is cured or has improved with appropriate antimicrobial treatment 3 -5 . This includes normalization of clinical parameters (body temperature, heart rate, respiratory rate, BP, oxygen saturation, mental status), inflammatory markers, findings on imaging, and microbiological eradication.
Patients with end-stage liver disease are at increased risk of infection with multidrug-resistant micro-organisms, which can have an adverse impact on outcome after transplantation 3, 6, 7 . This is particularly true for cephalosporin-or carbapenem-resistant Enterobacteriaceae 8 , methicillin-resistant Staphylococcus aureus 9 and vancomycin-resistant Enterococcus species 10 , the prevalence of which is increasing 11 .
Preoperative infection and outcome after liver transplantation e173 complex task because of the expansion of the so-called extended criteria donors. Donors are generally considered marginal if there is a risk of initial poor graft function or primary graft non-function 16, 17 . An unfavourable combination of high MELD score in the recipient and extended criteria donor could result in a forced choice dictated by time constraints for patients on the waiting list, often leading to a poor result 18 -21 . A recently cured or ongoing infection in the recipient complicates this scenario. Furthermore, transplant-related factors, such as prolonged ischaemia time, ischaemia-reperfusion injury, intraoperative blood transfusion and early complications after transplantation, can increase the risk of postoperative infections and/or recurrence of the infection 14,22 -24 . In the present study, the impact of bacterial infection within 1 month before deceased donor liver transplantation on mortality and complications after transplantation was assessed.
Methods
All adult patients who underwent liver transplantation from ABO-identical or ABO-compatible brain-dead organ donors at Sant'Orsola-Malpighi Hospital, University of Bologna, between 1 January 2010 and 31 December 2015 were selected from an institutional database. Demographic characteristics of the donors and recipients, and clinical, biochemical and surgical parameters were retrieved. Post-transplant survival rates and complications, including grade III-IV complications according to the Dindo-Clavien classification 25 , were compared between patients who had an infection 1 month before transplantation and patients who had no infection. The time frame of 1 month was chosen as indicated by previous studies 23, 24 . As complications tend to arise later in liver surgery compared with other surgical procedures, the postoperative course was defined as the period of 90 days after transplantation 26 .
The study was approved by the Institutional Review Board of Sant'Orsola-Malpighi Hospital (no. 62/2014/ O/Oss).
Definitions
Infections were defined according to the standard criteria proposed by the Centers for Disease Control and Prevention 27 . Clinical manifestations of infections were graded as sepsis, severe sepsis or septic shock, according to the definitions of the Surviving Sepsis Campaign Guidelines Committee 28 . Infection sites were categorized as intra-abdominal, lower respiratory tract, urinary tract, and skin and soft tissue. Intra-abdominal infections included spontaneous bacterial peritonitis, defined as a polymorphonucleated cell count of 250 cells/mm 3 or more in ascites, regardless of bacterial growth from culture 7 , with or without the presence of a peritoneal sign such as muscle guarding and/or rebound tenderness over the distended abdomen. The presence of bloodstream infection was also recorded, and classified as primary when the infection source was unidentified, as secondary in the presence of a determined infection site, and as catheter-related when the criteria of the Infectious Diseases Society of America guidelines 29 were fulfilled.
Gram-negative micro-organisms were classified as susceptible, multidrug-resistant, extensively drug-resistant or pan-drug-resistant, according to the European Society of Clinical Microbiology and Infectious Diseases and consensus definitions 30 . As for Gram-positive bacteria, methicillin-resistant Staphylococcus aureus, methicillin-resistant coagulase-negative staphylococci and Enterococcus faecium were classified as multidrug-resistant, and vancomycin-resistant Enterococcus species were classified as extensively drug-resistant.
Acute-on-chronic liver failure was defined as an acute decompensation of chronic liver disease, associated with organ failure(s), predefined by the Sequential Organ Failure Assessment -Chronic Liver Failure (SOFA-CLIF) score 2 ; it was diagnosed when at least one of the following signs was present 2 : single kidney failure; single liver, coagulation, circulation or respiration failure in patients with a serum creatinine level of 1⋅5-1⋅9 mg/dl and/or mild to moderate hepatic encephalopathy; single cerebral failure in patients with a serum creatinine concentration of 1⋅5-1⋅9 mg/dl.
The 'fatal triad' was defined as the need for dialysis, ventilatory support and vasopressor administration within 48 h before LT 31 .
Prolonged post-transplantation mechanical ventilation was defined as the need for mechanical ventilation for at least 72 h after surgery 32 .
Microbiology
Identification and susceptibility tests of isolated pathogens were carried out using the VITEK ® 2 system (bioMérieux, 33 . Hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-positive donors were allocated, without specific patient selection, to HBsAg-positive and hepatitis δ-negative patients respectively, with correct post-transplant antiviral prophylaxis. Hepatitis C virus (HCV)-positive donors were used for HCV-positive recipients 34 . Donor-MELD (D-MELD) 18, 19 , Donor Risk Index 35 and the Balance of Risk (BAR) 20 scores at transplant were also calculated retrospectively and compared between the groups.
All transplantations were performed with preservation of the recipient inferior vena cava 36 . Cell-saver ® (Haemonetics, Glasgow, UK) was used during surgery, but the volume of reinfused blood was calculated from the total volume of red blood cells transfused.
Immunosuppression was based on tacrolimus in combination with low-dose steroids, as reported previously 37, 38 . Induction therapies in combination with tacrolimus were administered in selected patients with combined transplants, autoimmune diseases, pretransplant renal insufficiency or positive cross-match. Patients with initial poor graft function (defined as an alanine or aspartate aminotransferase level above 2000 units/l or the need for fresh frozen plasma transfusion more than 5 days after transplant) 39 or primary graft non-function (defined as a graft not sustaining life and leading to retransplantation or death within 10 days after transplant) 39 were treated with an infusion of prostaglandin E1, when clinically feasible 40 . Acute cellular rejection episodes were treated with methylprednisolone pulse doses, with monoclonal antibodies reserved for those with steroid-resistant rejection. Recurrence of liver disease after transplant was always confirmed histologically 41 . For HCV recurrence, currently available antiviral treatment was offered to all patients, in the absence of contraindications.
Standard antibacterial prophylaxis consisted of shortterm administration of ampicillin-sulbactam. A different antimicrobial prophylaxis regimen was administered when an infectious episode had developed before transplantation, in order to complete the treatment, or in the case of donor-derived infections according to standard definitions 42 .
Antifungal prophylaxis was administered when specific risk factors for invasive fungal infection were present, as reported previously 43 . Cytomegalovirus (CMV)-seronegative patients who received an organ from a CMVpositive donor received oral valganciclovir 900 mg daily as post-transplant prophylaxis, until seroconversion. All CMV-seropositive recipients were screened weekly for CMV DNA by whole-blood quantitative PCR. If CMV DNA exceeded 100 000 copies/ml, patients were started on induction treatment with ganciclovir 5 mg/kg twice daily or oral valganciclovir 900 mg twice daily 44 . All patients were administered 160/800 mg trimethoprim/sulfamethoxazole three times weekly for 12 months after transplant, as prophylaxis for Pneumocystis jirovecii.
Statistical analysis
Results are expressed as median (range). Differences between continuous and categorical variables were calculated with the Mann-Whitney U test and χ 2 or Fisher's exact test respectively.
Continuous variables were analysed using the following cut-off values: for recipients, age less than 60 years or 60 years and older (median age of study population), BMI less than 25 kg/m 2 or 25 kg/m 2 and higher (median BMI of study population), MELD score below 21 or 21 and above (median MELD score of study population), D-MELD score 1628 or less or greater than 1628 18 , BAR score 18 or less or above 18 20 , cold ischaemia time less than 8 h or 8 h or more 45 , duration of transplant surgery less than 7 h or 7 h or above (median duration for the study population), red blood cell transfusion during surgery less than 2000 ml or 2000 ml or more 46 ; for donors, age less than 70 years or 70 years and older 47 , ICU stay less than 5 days or 5 days or more 47 , BMI less than 30 kg/m 2 or 30 kg/m 2 and above 35 , Donor Risk Index 1⋅8 or less or above 1⋅8 35 . Patient survival was calculated from the date of transplantation to the date of last follow-up or death. Graft survival Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Four patients with secondary bloodstream infection were also included in numbers for primary site of infection (intra-abdominal infection, 3; lower respiratory tract infection, 1). ‡Total of isolates is more than total of infections as some infections had polymicrobial aetiology.
rate was calculated from the date of transplantation to the date of last follow-up, death or graft loss. Actuarial survival was determined by the Kaplan-Meier method, and differences between groups were compared using the log rank test. To identify predictors of 90-day mortality univariable logistic regression was performed first for each variable investigated. Multivariable regression was then applied, selecting those variables significantly related to the outcome measure in the univariable analysis. This multivariable approach considered the relationships between some of the identified predictors. In detail, as the BAR score includes the MELD score, donor age, pretransplant organ dysfunction and retransplantation, only the variable with the highest χ 2 value was retained in the multivariable analysis to avoid overfitting the model. In addition, infection before liver transplantation was included in the multivariable analysis. P < 0⋅050 was considered statistically significant. Statistical analysis was carried out with SPSS ® software version 17.0 (IBM, Armonk, New York, USA).
Results
During the study period, 427 adults underwent liver transplantation from ABO-identical or ABO-compatible brain-dead organ donors at the authors' institution. In the same interval, 28 patients were removed from the waiting list because of infection, according to infective contraindications for liver transplantation; this included 19 patients with septic shock unresponsive to treatment, three with endocarditis and heart failure, three with respiratory failure due to lung and/or pleural bacterial infection, one with meningitis, one with respiratory failure due to pulmonary aspergillosis, and one with septic shock from bloodstream infection. Regarding aetiology, there were 22 bacterial infections (4 caused by carbapenem-resistant K. pneumoniae), two fungal infections, and four infections with an undetermined organism. Eighty-four patients (19⋅7 per cent) had a bacterial infection within 1 month before liver transplantation. Some 343 patients (80⋅3 per cent) had no documented infection in the last month before transplantation and formed the control group. Characteristics of the recipients and donors are shown in Table 1 . Patients with infection before liver transplantation had significantly more cholestatic liver disease and less hepatocellular carcinoma as an indication for transplant. Median MELD, D-MELD and BAR scores were also higher than in patients without infection. Table 2 shows the characteristics of infections before liver transplantation. A pathogen was isolated in 52 patients, and Values in parentheses are percentages unless indicated otherwise; *values are median (range). †Some patients had more than one grade III-IV complication. CVVH, continuous venovenous haemofiltration; HCV, hepatitis C virus. ‡χ 2 or Fisher's exact test, except §Mann-Whitney U test.
Enterobacteriaceae and Enterococcus species were responsible for 75 per cent of the infections. Resistant pathogens were isolated from 24 patients (29 per cent). The median time from infection to transplant was 18 (0-28) days, and that between discontinuation of antimicrobial treatment and transplant was 2 (0-25) days. Some 38 patients (45 per cent) had not completed antimicrobial treatment at transplantation. Outcome after liver transplantation is shown in Table 3 . The percentage of patients with grade III or IV postoperative complications was 42 per cent for patients with infection before transplantation versus 40⋅5 per cent for patients with no infection (P = 0⋅849). The type of complication was not significantly different between the groups. The rate of postoperative infection was significantly higher in patients who had an infection before transplantation: 48 per cent versus 30⋅6 per cent in those with no preoperative infection (P = 0⋅003). Colonization with carbapenem-resistant K. pneumoniae was greater in patients with infection before transplantation than in those with no infection: 29 versus 14⋅9 per cent respectively. Only one patient had a recurrent lower respiratory tract infection with the same multidrug-resistant bacteria isolated before transplant. In all other patients, post-transplant infections were caused by different pathogens and at different sites from pretransplant infections. Infection caused by resistant pathogens increased compared with that in the preoperative setting, with an overall rate of 47⋅6 per cent (69 of 145). The overall 90-day mortality rate was 6⋅8 per cent (29 of 427), and was not significantly different between the groups. Median follow-up was 32 (0-76) months. One-, 3-and 5-year overall survival rates were 88, 86 and 86 per cent for patients with infection before liver transplantation, and 88⋅5, 83⋅7 and 80⋅8 per cent for those without infection (P = 0⋅809) (Fig. 1a) . Corresponding graft survival is shown in Fig. 1b .
Analysis of factors affecting 90-day mortality
MELD, D-MELD and BAR scores, acute-on-chronic liver failure, retransplantation as indication for transplantation, and pretransplant organ dysfunction were associated with higher 90-day mortality in univariable analysis (Table S1 , supporting information). Independent predictors of 90-day mortality were: BAR score above 18 (P = 0⋅032) and onset of acute-on-chronic liver failure (P = 0⋅010). Infection before liver transplantation was not an independent predictor of mortality.
Discussion
In this study, patients with liver failure and concomitant infection 1 month before liver transplantation had a worse clinical condition than patients without infection. They had a higher rate of postoperative infection and more isolates with resistant bacteria. Despite the finding that nearly half of these patients did not complete antimicrobial treatment before transplantation and almost 30 per cent had multiresistant pathogens, they had no increased risk of postoperative complications or death. Multiple organ dysfunction, isolated liver failure and unfavourable donor-recipient matching were associated with a higher 90-day mortality rate, but none of these factors was an independent predictor of mortality. The main limitations of the study are its retrospective design, the small sample size and the lack of well established de-listing criteria owing to pretransplant infection. which may limit validity and generalization.
Previous studies have reported on the impact of pretransplant bacterial infection on the outcome after liver transplantation. Sun and colleagues 22 included 32 patients with at least one bacterial infection within 12 months before transplantation. They showed that these patients had a higher MELD score, were more frequently hospitalized, and required longer post-transplant care. However, post-transplant survival was comparable between patients with and those without infection 22 . Hara and co-workers 24 reported that 20 patients undergoing living-donor liver transplantation with an infection diagnosed within 1 month before transplant had a lower 1-year post-transplant survival rate than 30 patients without infection (65 versus 86 per cent respectively). The present study included 84 patients with end-stage liver disease and infection occurring shortly before transplantation, and has also demonstrated that following antimicrobial treatment liver transplantation should not be withheld in these patients.
Patients with infection before transplant did not have any advantage in terms of donor choice, as donor age and Donor Risk Index were comparable with values in the control group. In particular, median donor age was around 60 years in both study groups. Conversely, BAR and D-MELD scores, which have both recently been proposed to balance donor and recipient features 18 -20 , were significantly worse in patients with an infection. These variables have not been analysed previously 22 -24 . Other factors, including prolonged ischaemia time and ischaemia-reperfusion injury, are associated with a higher incidence of postoperative infection 14 . The present study demonstrates that donor characteristics per se had no impact on the incidence of post-transplant infection, even in patients with infection before liver transplantation. This is in line with previous studies that had a policy of minimizing cold ischaemia time and systematic real-time liver graft biopsy 47 -49 . Multidrug resistance is an increasing problem worldwide 6 -8,11,30 and is a risk factor for mortality in pretransplant and post-transplant patients with end-stage liver disease due to compromised immune function 3,8 -10,12,13 . In the present study, despite the high rate of pretransplantresistant microbial isolates and the high proportion of multidrug-resistant organisms found after transplant, neither early nor late mortality was affected. As in previous studies 23 , infections after transplant were at different sites and different pathogens were isolated, compared with pretransplant infections. This suggests that the infections occurring before liver transplantation had been treated successfully. Although a diseased liver has a reduced capacity to clear bacteria, a well functioning graft protects the patient from infection. This counteracts the potentially negative effect of a major operation and the use of immunosuppressive drugs, leading to a favourable balance in immunosuppression 50 . As infections reflect an immunocompromised state, the use of an immune response assay should be particularly useful in liver transplant recipients with pretransplant infection, in order to optimize immunosuppression and decrease the risk of further infective episodes 51 .
However, acute decompensation of chronic liver disease had the strongest impact on postoperative mortality, as reported by others 2, 12, 52 . This is an important factor limiting access to liver transplantation in patients with infection. In fact, the therapeutic window for proposing transplantation in patients with acute-on-chronic liver disease is very narrow, and clinical deterioration often represents the main argument for removing these patients from the waiting list. To avoid the patient reaching the point of being too ill to undergo transplantation 53 , it seems reasonable not to wait for complete resolution of the infection. Finally, the present study has confirmed that the BAR score is a strong predictor of 90-day mortality, as reported previously 20, 47, 54 , and may represent a valid tool in clinical practice to evaluate the indication for liver transplantation 54 .
